Ketogenic Diet Research

This meta-analysis of 11 RCTs (19 reports, 2001-2021) compared ketogenic diets to control diets in adults with type 2 diabetes for interventions lasting more than 14 days.

The headline finding was negative for keto's primary claimed benefits: no significant difference in glycemic control (HbA1c) or body weight compared to control diets. However, keto did improve lipid profiles — HDL cholesterol increased (SMD 0.19, moderate-quality evidence) and triglycerides decreased (SMD -0.41, low-quality evidence).

This is an important reality check: while keto may improve certain cardiovascular markers in diabetics, it doesn't outperform standard dietary approaches for the primary goals of blood sugar management and weight loss over longer timeframes.

This systematic review of reviews evaluated the effectiveness of various ketogenic dietary therapies for treating refractory (drug-resistant) epilepsy specifically in children and adolescents. The authors comprehensively analyzed existing systematic reviews and meta-analyses to consolidate the evidence on the classic ketogenic diet, modified Atkins diet, low glycemic index treatment, and medium-chain triglyceride diet in pediatric populations.

The findings consistently show that ketogenic dietary therapies produce clinically significant seizure reductions in a substantial portion of pediatric patients who have failed to respond to antiepileptic medications. The classic ketogenic diet with a 4:1 fat-to-carbohydrate ratio tended to show the strongest efficacy, though less restrictive variants like the modified Atkins diet also demonstrated meaningful seizure control with potentially better adherence and tolerability in older children and adolescents.

The review highlights that despite the consistent positive findings across multiple reviews, the overall quality of evidence remains moderate due to reliance on observational studies and the inherent difficulty of conducting blinded dietary trials. The authors call for more rigorous randomized controlled trials and emphasize the importance of individualized dietary approaches based on patient age, seizure type, and family capacity.

This umbrella review — the highest level of evidence synthesis — examined 17 meta-analyses comprising 68 RCTs across 115 health associations for ketogenic diets. It graded evidence quality for each outcome.

High-quality evidence (4 associations) supported reduced triglycerides, decreased seizure frequency, and reduced seizure severity, but also elevated LDL cholesterol. Moderate-quality evidence (4 associations) supported body weight reduction, lower HbA1c, decreased respiratory exchange ratio, and elevated total cholesterol. The remaining 43 significant associations were supported by low-to-very-low quality evidence.

Very low-calorie ketogenic diets improved body composition without worsening muscle mass, but standard ketogenic low-carb high-fat diets reduced muscle mass in healthy populations. The authors recommend long-term follow-up trials to determine whether short-term metabolic improvements translate to reduced cardiovascular events and mortality.

This paper provides a comprehensive overview of existing systematic reviews and meta-analyses evaluating the ketogenic diet (KD) as a treatment for epilepsy. The authors synthesized evidence from multiple high-level reviews to assess the overall efficacy, safety, and tolerability of ketogenic dietary therapies, including the classic KD, modified Atkins diet (MAD), and medium-chain triglyceride (MCT) diet.

The aggregated evidence demonstrates that ketogenic dietary therapies are effective for reducing seizure frequency in patients with drug-resistant epilepsy across both pediatric and adult populations. The analysis found that a substantial proportion of patients achieve clinically meaningful seizure reduction, with some attaining complete seizure freedom. The authors also reviewed the side effect profile, noting that while gastrointestinal symptoms, dyslipidemia, and kidney stones can occur, these are generally manageable with appropriate monitoring.

The overview concludes that ketogenic dietary therapies represent a valuable treatment option for drug-resistant epilepsy, supported by a robust body of systematic review evidence. The authors recommend further high-quality randomized controlled trials to strengthen the evidence base and better define optimal dietary protocols.

This comprehensive review examines the therapeutic potential of the ketogenic diet for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The authors synthesize evidence from both preclinical and clinical studies to evaluate the neuroprotective mechanisms of ketone bodies and the practical application of ketogenic dietary interventions in neurodegeneration.

The review describes several key neuroprotective mechanisms of the ketogenic diet. Ketone bodies (beta-hydroxybutyrate and acetoacetate) serve as alternative brain fuel, bypassing impaired glucose metabolism that characterizes many neurodegenerative conditions. The diet also enhances mitochondrial function, reduces oxidative stress, modulates neuroinflammation through NLRP3 inflammasome inhibition, and influences the gut-brain axis through changes in the microbiome. These mechanisms collectively address multiple pathological processes underlying neurodegeneration.

While preclinical evidence is promising and some early clinical studies show cognitive improvements in Alzheimer's patients and motor function benefits in Parkinson's patients, the authors note that large-scale clinical trials are still lacking. They conclude that the ketogenic diet represents a promising non-pharmacological approach for neurodegenerative diseases but emphasize the need for well-designed randomized controlled trials to establish clinical efficacy and optimal protocols.

Published in Cell Metabolism, this landmark study assigned C57BL/6 mice to ketogenic, low-carb, or control diets starting at 12 months of age (roughly middle-aged). Mice either lived out their natural lifespan or underwent physiological testing after 1-14 months of intervention.

The ketogenic diet significantly increased median lifespan and survival compared to controls. Beyond just living longer, KD mice maintained healthspan — they preserved novel object recognition (memory), grip strength, and motor performance into old age while control mice declined.

At the molecular level, the ketogenic diet increased protein acetylation and regulated mTORC1 signaling in tissue-dependent patterns, suggesting mechanisms similar to calorie restriction's longevity benefits. This was one of two simultaneous Cell Metabolism papers (the other by Newman et al.) establishing that ketogenic diets can extend both lifespan and healthspan in mammals.

This comprehensive review examined the evidence for ketogenic diets beyond simple weight loss, including effects on metabolic health, neurological conditions, and potential longevity benefits.

This study examined whether a very low-carbohydrate diet could improve cognitive function in older adults with mild cognitive impairment (MCI), testing the hypothesis that ketones provide an alternative brain fuel.